Curis Inc Q4 revenue misses estimates

Curis

19/03/2026 20:12

Overview

US biotechnology firm's Q4 revenue fell and missed analyst expectations

Outlook

Curis expects current cash and planned warrant proceeds to fund operations into the second half of 2027

Result Drivers

ROYALTY ASSET SALE - Co recognized $27.2 mln non-cash gain and extinguished liability from sale of Erivedge royalty assets

Company press release: ID:nPn33cwXka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$1.14 mln
$3.19 mln (5 Analysts)
Q4 Net Income
Beat
$19.36 mln
-$7.78 mln (5 Analysts)
Q4 Basic EPS
Beat
$1.23
-$0.45 (5 Analysts)
Q4 Income From Operations
Beat
$19.62 mln
-$7.32 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Curis Inc is $17.00, about 1,985.6% above its March 18 closing price of $0.82

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)